Pediatric Glioma Trials Combine Therapies to Combat Resistance

Researchers presented findings from two clinical trials at the International Symposium on Pediatric Neuro-Oncology (ISPNO) that are investigating combination therapy strategies to overcome treatment resistance in pediatric low-grade gliomas. These gliomas are the most common type of brain tumor in children, and while BRAF/MEK inhibitors have shown efficacy, many patients develop resistance, leading to tumor recurrence and progression. The trials aim to identify more effective treatment regimens by combining targeted therapies with other agents.

One trial, a Phase 1/2 study, is evaluating the combination of dabrafenib and trametinib with everolimus in patients with recurrent or refractory pediatric low-grade gliomas harboring BRAF alterations. Dabrafenib is a BRAF inhibitor, and trametinib is a MEK inhibitor, both of which target specific genetic mutations common in these tumors. Everolimus is a mammalian target of rapamycin (mTOR) inhibitor, a pathway that can also be involved in tumor growth and resistance mechanisms. The initial results from this trial, presented at ISPNO, indicated that the combination was generally well-tolerated, with preliminary signs of clinical activity. Specific response rates and duration of response are being closely monitored as the trial progresses. The study is designed to assess safety, tolerability, and preliminary efficacy, paving the way for further investigation.

A second trial, also presented at ISPNO, is exploring a different combination approach. This study is investigating the use of selumetinib, another MEK inhibitor, in combination with chemotherapy agents in pediatric patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas, which are often considered a precursor to low-grade gliomas and share some molecular pathways. While not directly a glioma trial, it highlights the broader effort to tackle resistance in related pediatric tumor types. The rationale for combining MEK inhibitors with chemotherapy is to exploit synergistic effects, where the combined treatment is more effective than either agent alone. Early data from this trial suggest that the combination can lead to tumor shrinkage and improved quality of life for affected children. Both trials underscore the critical need for novel therapeutic strategies to improve outcomes for children with these challenging brain tumors, moving beyond single-agent targeted therapy to more comprehensive treatment plans.